OBIO Orchestra BioMed Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1814114 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,007.4%
TTM net income YoY24.2%
TTM EPS YoY58.3%
Revenue 3-yr CAGR105.4%
Net income 3-yr CAGR—
Margins
Gross margin99.6%
Operating margin-195.4%
Net margin-182.5%
FCF margin-205.7%
EBITDA margin-194.2%
Returns
ROE-221.1%
ROA-53.6%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets82.6%
Debt / equity0.00x
Current ratio7.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.11x
Accruals ratio6.0%
Payout ratio—
Capex / revenue2.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $91,000 | $88,000 | $110,000 | $30.92M | $861,000 | $836,000 | $868,000 | $253,000 |
| Cost of revenue | $28,000 | $25,000 | $32,000 | $51,000 | $49,000 | $46,000 | $44,000 | $58,000 |
| Gross profit | $63,000 | $63,000 | $78,000 | $30.87M | $812,000 | $790,000 | $824,000 | $195,000 |
| R&D expense | $17.73M | $16.59M | $15.78M | $16.82M | $14.03M | $13.85M | $13.48M | $10.97M |
| SG&A expense | $5.62M | $5.83M | $6.37M | $7.29M | $7.10M | $6.26M | $6.26M | $5.90M |
| Operating income | -$23.30M | -$22.36M | -$22.08M | $6.75M | -$20.31M | -$19.33M | -$18.92M | -$16.68M |
| Interest expense | — | — | — | — | — | — | — | $297,000 |
| Net income | -$18.75M | -$23.75M | -$20.69M | $6.25M | -$20.83M | -$19.36M | -$18.75M | -$16.16M |
| EBITDA | -$23.20M | -$22.26M | -$21.99M | $6.84M | -$20.23M | -$19.25M | -$18.84M | -$16.59M |
| EPS (basic) | -0.30 | -0.38 | -0.33 | — | -0.40 | -0.50 | -0.49 | — |
| EPS (diluted) | -0.30 | -0.38 | -0.33 | — | -0.40 | -0.50 | -0.49 | — |
| Weighted avg. shares (diluted) | 64.62M | 63.81M | 62.72M | — | 52.19M | 38.39M | 38.24M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $27.76M | $20.47M | $28.37M | $34.69M | $42.01M | $18.75M | $18.35M | $22.26M |
| Short-term investments | $74.15M | $89.49M | $66.03M | $71.82M | $53.81M | $15.18M | $31.54M | $44.55M |
| Receivables | $56,000 | $51,000 | $84,000 | $95,000 | $52,000 | $83,000 | $89,000 | $92,000 |
| Inventory | $221,000 | $250,000 | $277,000 | $310,000 | $365,000 | $185,000 | $135,000 | $173,000 |
| Current assets | $103.17M | $111.24M | $96.21M | $107.91M | $97.77M | $35.88M | $51.90M | $69.17M |
| PP&E, net | $2.28M | $2.04M | $1.85M | $1.72M | $1.59M | $1.37M | $1.41M | $1.38M |
| Total assets | $107.74M | $115.70M | $100.66M | $114.86M | $104.81M | $42.83M | $59.05M | $76.17M |
| Current liabilities | $14.23M | $13.47M | $13.69M | $16.74M | $20.66M | $17.06M | $15.49M | $16.21M |
| Long-term debt | — | — | $15.00M | $15.00M | $15.00M | $15.00M | $15.00M | $15.00M |
| Total debt | — | — | $15.00M | $15.00M | $15.00M | $15.00M | $15.00M | $15.00M |
| Total liabilities | $88.99M | $86.28M | $49.69M | $51.48M | $61.07M | $42.53M | $42.19M | $43.22M |
| Shareholders' equity | $7.78M | $19.32M | $41.19M | $53.57M | $43.74M | $295,000 | $16.86M | $32.96M |
| Net debt | — | — | -$13.37M | -$19.69M | -$27.01M | -$3.75M | -$3.35M | -$7.26M |
| Shares outstanding | 61.45M | 60.11M | 58.63M | 57.03M | 56.46M | 38.64M | 38.31M | 38.19M |
| Cash flow statement | ||||||||
| Operating cash flow | -$19.54M | -$19.33M | -$22.17M | -$2.27M | -$14.55M | -$15.53M | -$16.62M | -$13.54M |
| Capital expenditure | $398,000 | $254,000 | $184,000 | $33,000 | $310,000 | $34,000 | $112,000 | $106,000 |
| Free cash flow | -$19.94M | -$19.59M | -$22.35M | -$2.30M | -$14.86M | -$15.56M | -$16.73M | -$13.64M |
| Investing cash flow | $20.96M | -$23.31M | $10.32M | -$17.71M | -$38.58M | $16.36M | $13.00M | -$3.75M |
| Financing cash flow | $5.86M | $34.75M | $5.53M | $12.66M | $76.40M | -$428,000 | -$296,000 | $13.95M |
| Depreciation & amortization | $101,000 | $96,000 | $90,000 | $82,000 | $81,000 | $81,000 | $83,000 | $84,000 |
| Stock-based compensation | $2.29M | $2.50M | $2.85M | $2.75M | $3.01M | $3.25M | $2.96M | $2.90M |
Free plan shows the latest 8 periods; Pro shows all 24 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.